Area under the curve (AUC) is a very important parameter for determination of optimal dosage of antineoplastic agents in order to avoid side effects and achieve high effectiveness. Also, even if a certain dosage is administered, measured AUC is different in each individual. Therefore, it is important to determine the formula of the dosage of antineoplastic agents. We treated oral cancer using an intra-arterial infusion chemotherapy with nedaplatin (CDGP). Eighteen patients were treated with CDGP at the Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa Medical University, from October 1998 to June 2002. The correlation among expected AUC, dosage, CDGP clearance and 24 hr creatinine clearance in all chemotherapy was monitored and examined. The obtained formula in the dosage of intra-arterial infusion chemotherapy with Nedaplatin was as follows. dosage = AUC x (0.027 x CCr + 7.17).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dosing optimisation of intravenous lidocaine in patients with class 1-3 obesity by population pharmacokinetic analysis.
Anaesthesia
January 2025
Department of Anaesthesia and Perioperative Medicine, The Royal Brisbane and Women's Hospital, Brisbane, Australia.
Article Synopsis
- The study focused on developing an optimized lidocaine dosing regimen for obese patients during surgery, highlighting the need for more effective pain management.
- Researchers gathered data from 30 patients, measuring plasma levels of lidocaine and its metabolites to create a pharmacokinetic model.
- The findings suggested that current dosing was often inadequate, but an adjusted regimen could improve the likelihood of reaching therapeutic drug concentrations.
Continuous intra-arterial infusion chemotherapy using a port-catheter for nasopharyngeal carcinoma.
J Vasc Interv Radiol
December 2024
Department of Interventional Radiology, Hospital Israelita Albert Einstein, Sao Paulo, (SP), Brazil.
Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.
J Med Case Rep
December 2024
Liver Cancer Institute, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China.
Background: Tumor lysis syndrome is a life-threatening complication in the treatment of cancer. However, it rarely occurs in solid tumors, especially in hepatocellular carcinoma.
Case Presentation: We present a 52-year-old male Asian patient with advanced hepatocellular carcinoma treated with hepatic artery infusion chemotherapy that resulted in tumor lysis syndrome.
Arterial Infusion and Isolated Perfusion in Combination with Reversible Electroporation for Locally Relapsed Unresectable Breast Cancer.
Cancers (Basel)
November 2024
Department Surgical Oncology, Medias Klinikum, 84489 Burghausen, Germany.
Background: Relapsed unresectable triple-negative breast cancer is a demanding disease with only a few treatment options. Especially for patients with unresectable tumor masses, a treatment that offers rapid tumor shrinkage is needed. If patients are exhausted from several treatment lines, systemic side effects have to be avoided.
View Article and Find Full Text PDFFOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.
Front Immunol
December 2024
Department of General Surgery, Hepatobiliary Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Background: Hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen has demonstrated efficacy in patients with unresectable hepatocellular carcinoma (HCC). The combined targeted and immunotherapy has emerged as a first-line treatment for liver cancer. In this study, we investigated the clinical efficacy and safety of FOLFOX-HAIC in combination with targeted immunotherapy in patients with untreated, unresectable HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!